Edition:
United States

Agilent Technologies Inc (A.N)

A.N on New York Stock Exchange

68.79USD
17 Nov 2017
Change (% chg)

$0.05 (+0.07%)
Prev Close
$68.74
Open
$68.53
Day's High
$69.09
Day's Low
$68.29
Volume
576,957
Avg. Vol
447,621
52-wk High
$69.09
52-wk Low
$42.92

Chart for

About

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $22,138.55
Shares Outstanding(Mil.): 321.83
Dividend: 0.15
Yield (%): 0.87

Financials

  Industry Sector
P/E (TTM): -- 30.95 15.79
EPS (TTM): -- -- --
ROI: -- 10.03 12.01
ROE: -- 15.31 15.91

BRIEF-Agilent technologies increases cash dividend to 14.9 cents per share

* Agilent technologies increases cash dividend to 14.9 cents per share Source text for Eikon: Further company coverage:

Nov 15 2017

Exclusive: Siemens mandates three banks for IPO of Healthineers unit - sources

FRANKFURT Germany's Siemens AG has mandated Goldman Sachs , Deutsche Bank and JP Morgan as lead organizers of an initial public offering (IPO) of its Healthineers unit, sources familiar with the matter said.

Oct 24 2017

BRIEF-Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx

* Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer Source text for Eikon: Further company coverage:

Sep 22 2017

BRIEF-Agilent Technologies announces sponsorship deal with LabCentral

* Announced platinum sponsorship agreement with LabCentral, co to equip LabCentral's shared laboratory workspace with co's technology​

Sep 19 2017

BRIEF-Agilent announces expanded use of cancer diagnostic in U.S.

* Says ‍FDA approved cancer diagnostic for use in cases of UC and of Squamous Cell Carcinoma of head & neck​ Source text for Eikon: Further company coverage:

Sep 19 2017

BRIEF-AGILENT OBTAINS U.S. FDA APPROVAL FOR GENETISURE DX POSTNATAL ASSAY

* AGILENT OBTAINS U.S. FDA APPROVAL FOR GENETISURE DX POSTNATAL ASSAY

Sep 13 2017

BRIEF-Agilent Technologies files lawsuit against Shanghai Echrom Electronic and former employees

* FILED A CIVIL LAWSUIT AGAINST SHANGHAI ECHROM ELECTRONIC TECHNOLOGY CO LTD AND SEVERAL FORMER EMPLOYEES OF AGILENT

Aug 22 2017

BRIEF-Agilent Technologies reports Q3 non-GAAP earnings per share of $0.59

* Agilent Technologies reports third-quarter fiscal year 2017 financial results

Aug 15 2017

BRIEF-Agilent acquires Next Generation Sequencing IP portfolio

* Agilent acquires powerful Next Generation Sequencing IP portfolio

Jul 24 2017

BRIEF-Agilent Technologies increased size of board from 10 to 11 members

* Agilent Technologies- increased size of board from 10 to 11 members, appointed Hans E. Bishop to fill vacancy so created, both effective July 18, 2017 Source text: (http://bit.ly/2tG4yhU) Further company coverage:

Jul 19 2017

Earnings vs. Estimates